Evidence map›Paper›PMID 30671889›Full record

ArticleInternational urology and nephrology2019

Whole mount histopathological correlation with prostate MRI in Grade I and II prostatectomy patients.

Michael Wang, Nafiseh Janaki, Christina Buzzy, Laura Bukavina, Amr Mahran, Kirtishri Mishra, Gregory MacLennan, Lee Ponsky

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Exploring the potential ofProstate international · 2024
    Article
  2. Review
  3. Prostate zones and cancer: lost in transition?Nature reviews. Urology · 2022
    Review
  4. Article
  5. Article
  6. Article
  7. Mri-based cancer lesion analysis with 3d printed patient specific prostate cutting guides.American journal of clinical and experimental urology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michael WangDivision of Urologic Oncology, Urology Institute, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
Nafiseh JanakiDepartment of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Christina BuzzyDivision of Urologic Oncology, Urology Institute, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
Laura BukavinaDivision of Urologic Oncology, Urology Institute, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
Amr MahranDivision of Urologic Oncology, Urology Institute, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
Kirtishri MishraDivision of Urologic Oncology, Urology Institute, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
Gregory MacLennanDepartment of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Lee PonskyDivision of Urologic Oncology, Urology Institute, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA. Lee.Ponsky@UHhospitals.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiparametric magnetic resonance imaging (mpMRI) is increasingly used in detection and surveillance of prostate cancer. However, the co-localization of lower grade lesions between mpMRI and histopathologic specimen has not been well established.

objectiveWe aim to determine the factors on final histopathological exam that correlate to tumor visibility for Grade I and II disease on mpMRI.

methodsFifty-five patients who underwent radical prostatectomy from July 2014 to June 2016 were analyzed for the study. Of the sample of 55 patients, 18 were found to have Gleason score (GS) of 3 + 3 or 3 + 4 disease, and then were re-reviewed and annotated by a pathologist. Lesion diameter, area, and distance from the prostate capsule were measured. The annotated lesions were co-localized to the MRI report.

resultsOf the 184 lesions identified on the whole mount histopathologic slides, 106 (57.6%), 62 (33.7%), 14 (7.6%), and 2 (1.1%) of the lesions had a GS of 3 + 3, 3 + 4, 4 + 3, and 4 + 4, respectively. On analysis, 27.3% (24/88) of GS 6 (< 1.5 cm in size), and 88.9% (16/18) of GS 6 (> 1.5 cm in size) were identified (p < 0.001). Additionally, when assessing lesion proximity to the prostatic capsule, 46.1% (41/89) of lesions closer (≤ 0.05 cm), and 30.5% (29/95) of lesions further (> 0.05 cm) from the capsule were visualized.

conclusionLesion diameter, area, and capsule proximity correlated with MRI visibility. Further studies are encouraged to validate the findings of our study.

Indexed as

AgedHistocytological Preparation TechniquesHumansMagnetic Resonance ImagingMaleMiddle AgedNeoplasm GradingProstatectomyProstatic NeoplasmsRetrospective StudiesTumor BurdenHistopathologyIntermediate prostate cancerMultiparametric MRIProstate cancer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.